» Articles » PMID: 35841085

Biomarker Discovery for Practice of Precision Medicine in Hypopharyngeal Cancer: a Theranostic Study on Response Prediction of the Key Therapeutic Agents

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Jul 15
PMID 35841085
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypopharyngeal cancer is a relatively rare malignancy with poor prognosis. Current chemotherapeutic algorithm is still far from personalized medicine, and the identification of the truly active therapeutic biomarkers and/or targets is eagerly awaited.

Methods: Venturing to focus on the conventional key chemotherapeutic drugs, we identified the most correlative genes (and/or proteins) with cellular sensitivity to docetaxel (TXT), cisplatin (CDDP) and 5-fluorouracil (5-FU) in the expression levels, through 3 steps approach: genome-wide screening, confirmation study on the quantified expression levels, and knock-down and transfection analyses of the candidates. The probable action pathways of selected genes were examined by Ingenuity Pathway Analysis using a large-scale database, The Cancer Genome Atlas.

Results: The first genome-wide screening study derived 16 highly correlative genes with cellular drug sensitivity in 15 cell lines (|R| > 0.8, P < 0.01 for CDDP and 5-FU; |R| > 0.5, P < 0.05 for TXT). Among 10 genes the observed correlations were confirmed in the quantified gene expression levels, and finally knock-down and transfection analyses provided 4 molecules as the most potent predictive markers-AGR2 (anterior gradient 2 homolog gene), and PDE4D (phosphodiesterase 4D, cAMP-specific gene) for TXT; NINJ2 (nerve Injury-induced protein 2); CDC25B (cell division cycle 25 homolog B gene) for 5-FU- in both gene and protein expression levels. Overexpression of AGR2, PDE4D signified worse response to TXT, and the repressed expression sensitized TXT activity. Contrary to the findings, in the other 2 molecules, NINJ2 and CDC25, there observed opposite relationship to cellular drug response to the relevant drugs. IPA raised the potential that each selected molecule functionally interacts with main action pathway (and/or targets) of the relevant drug such as tubulin β chain genes for TXT, DNA replication pathway for CDDP, and DNA synthesis pathway and thymidylate synthetase gene for 5-FU.

Conclusion: We newly propose 4 molecules -AGR2, PDE4D,NINJ2 and CDC25B) as the powerful exploratory markers for prediction of cellular response to 3 key chemotherapeutic drugs in hypopharyngeal cancers and also suggest their potentials to be the therapeutic targets, which could contribute to the development of precision medicine of the essential chemotherapy in hypopharyngeal patients. (339 words).

Citing Articles

AGR2: The Covert Driver and New Dawn of Hepatobiliary and Pancreatic Cancer Treatment.

Qu S, Jia W, Nie Y, Shi W, Chen C, Zhao Z Biomolecules. 2024; 14(7).

PMID: 39062458 PMC: 11275012. DOI: 10.3390/biom14070743.

References
1.
Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J . Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. Int J Oncol. 2006; 28(5):1153-62. View

2.
Zhou R, Liu D, Zhu J, Zhang T . Common gene signatures and key pathways in hypopharyngeal and esophageal squamous cell carcinoma: Evidence from bioinformatic analysis. Medicine (Baltimore). 2020; 99(42):e22434. PMC: 7571924. DOI: 10.1097/MD.0000000000022434. View

3.
Xie C, Lin P, Hao J . Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance. Biomedicines. 2021; 9(5). PMC: 8151738. DOI: 10.3390/biomedicines9050538. View

4.
Rokudai S, Li Y, Otaka Y, Fujieda M, Owens D, Christiano A . STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis. Proc Natl Acad Sci U S A. 2018; 115(21):E4806-E4814. PMC: 6003458. DOI: 10.1073/pnas.1718546115. View

5.
Maloney S, Hoover C, Morejon-Lasso L, Prosperi J . Mechanisms of Taxane Resistance. Cancers (Basel). 2020; 12(11). PMC: 7697134. DOI: 10.3390/cancers12113323. View